PSTV

Plus Therapeutics Announces Selection of “Rhenium (186Re) Obisbemeda” as International Non-Proprietary Name for 186RNL

Retrieved on: 
Mercoledì, Ottobre 26, 2022
Company, PSTV, Safety, Cancer, Nasdaq, U.S. Securities and Exchange Commission, Joint FAO/WHO Expert Committee on Food Additives, Glioblastoma, Neoplasm, Patient, World, International, Research, GLOBE, Therapy, WHO, Liposome, INN, Radiation, Perception, Pharmaceutical industry, Rhenium

Going forward, Plus Therapeutics will use Rhenium (186Re) obisbemeda in place of 186RNL.

Key Points: 
  • Going forward, Plus Therapeutics will use Rhenium (186Re) obisbemeda in place of 186RNL.
  • Plus Therapeutics, Inc. isa clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases.
  • Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology.
  • This press release contains statements that may be deemed forward-looking statements within the meaning of U.S. securities laws.

Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Giovedì, Ottobre 20, 2022
U.S. Securities and Exchange Commission, European Society for Medical Oncology, Congress, Education, GBM, Pakistan Society of Neuro-Oncology, Therapy, Webcast, Achievement, Neoplasm, Hand, GMP, CGMP, PSTV, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Perception, EANM, NIH, Research, CMC, Nasdaq, Cancer, Food, SNO, Oncology, Company, Liposome, National, Society, Association, Nuclear medicine, Safety, LM, GLOBE, ESMO, Radiation, European Association of Urology, Cohort, FDA, Pharmaceutical industry

AUSTIN, Texas, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the third quarter ended September 30, 2022, and provided an overview of recent business highlights.

Key Points: 
  • ET
    AUSTIN, Texas, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the Company), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the third quarter ended September 30, 2022, and provided an overview of recent business highlights.
  • The third quarter of 2022 was another period of significant progress for Plus Therapeutics, highlighted by the achievement of three key milestones, said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
  • Second, we moved 186RNL toward a Phase 2 trial for recurrent GBM, which we expect to initiate in the fourth quarter of 2022.
  • The Phase 1 results demonstrated safety and a potential efficacy signal in heavily pretreated patients with recurrent GBM.

Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress

Retrieved on: 
Mercoledì, Ottobre 19, 2022
U.S. Securities and Exchange Commission, GBM, Therapy, CSF, Neoplasm, National Institute for Health and Care Excellence, CGMP, SubArachnoid Space, PSTV, Patient, Perception, EANM, Research, NIH, Nasdaq, Senior, Cancer, Company, Liposome, Plus, Cerebrospinal fluid, National, Association, Nuclear medicine, Adult, Safety, LM, CNS, Survival, Radiation, GLOBE, Grey, European Association for the Study of the Liver, Glioblastoma, Survival rate, Feasibility, Top-rated United States television programs by season, Pharmaceutical industry, Medical imaging

AUSTIN, Texas, Oct. 19, 2022 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, presented data from two ongoing clinical trials evaluating the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM) at the 35th Annual Congress of the European Association of Nuclear Medicine (EANM). The Company’s ReSPECT-GBM presentation was selected for inclusion in the opening Plenary Highlights Lecture, signaling significant clinical interest in the field.

Key Points: 
  • The Companys ReSPECT-GBM presentation was selected for inclusion in the opening Plenary Highlights Lecture, signaling significant clinical interest in the field.
  • Combined with our Phase 1 data in recurrent glioblastoma, these presentations reinforce the tremendous potential of 186RNL as a versatile radiotherapeutic treatment option for multiple CNS cancers.
  • All patients showed a decreased CSF cell count by microfluidic chamber assay after treatment, ranging from 46% to 92%.
  • Cohort 2 in the ReSPECT-LM trial has commenced, with interim data from the first two patient cohorts expected by the end of 2022.

Plus Therapeutics to Present at the ThinkEquity Conference

Retrieved on: 
Martedì, Ottobre 18, 2022
U.S. Securities and Exchange Commission, Therapy, Neoplasm, Conference, PSTV, Patient, Perception, Research, Cancer, Mandarin Oriental Hotel Group, Company, Plus, Safety, GLOBE, Radiation, Pharmaceutical industry

The conference is being held at the Mandarin Oriental, New York in New York City.

Key Points: 
  • The conference is being held at the Mandarin Oriental, New York in New York City.
  • Investors interested in arranging a meeting with the Companys management during the conference should contact the conference coordinator.
  • An archived replay of the presentation will be available under the Events tab of the Plus Therapeutics website at www.plustherapeutics.com for 90 days following the event.
  • Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases.

Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022

Retrieved on: 
Giovedì, Ottobre 6, 2022
U.S. Securities and Exchange Commission, Therapy, Webcast, Neoplasm, PSTV, Patient, Perception, Research, Program, Nasdaq, Cancer, Company, Safety, LM, GLOBE, Radiation, Pharmaceutical industry

Plus Therapeutics management team will then host a conference call and webcast at 5:00 p.m.

Key Points: 
  • Plus Therapeutics management team will then host a conference call and webcast at 5:00 p.m.
  • ET to discuss the financial results and provide a corporate update.
  • Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call.
  • Following the live call, a replay will be available on the Companys website under the 'For Investor' section.

Plus Therapeutics Announces Patient Webinar in Recognition of Breast Cancer Awareness Month

Retrieved on: 
Mercoledì, Ottobre 5, 2022
Therapy, IND, Neoplasm, PSTV, Investor, Perception, Texas Tech University Health Sciences Center, Program, Texas A&M University, Lung cancer, Liposome, Texas Oncology, UTHSCSA, Membrane, Scott, Co-leader of the Scottish Green Party, Cancer, SPA, Internal medicine, Company, Cerebrospinal fluid, Neurology, GLOBE, FDA, Biochemistry, Principal, PD, Research, Neurosurgery, DPM, Development of the human body, Radiation, Experiment, University, Hematology, Data analysis, MicroRNA, U.S. Securities and Exchange Commission, Cros, Spinal cord, University of Texas Health Science Center at San Antonio, Education, Patient, Private practice, Nasdaq, Safety, LM, Brain, Oncology, University of Texas System, Pharmaceutical industry, Risk management, Breast cancer

Leptomeningeal metastases is a cancer in the cerebrospinal fluid and in the membranes surrounding the brain and spinal cord, occurring as a result of an advanced cancer spreading.

Key Points: 
  • Leptomeningeal metastases is a cancer in the cerebrospinal fluid and in the membranes surrounding the brain and spinal cord, occurring as a result of an advanced cancer spreading.
  • It is most common in breast cancer, but does occur in lung cancer and other cancers.
  • The event, part of the Musella Foundation Webinar Series, is to be presented live on the Foundations website at virtualtrials.com/webinar/ through a Zoom room.
  • Plus Therapeutics, Inc. isa clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases.

Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT™ Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Martedì, Ottobre 4, 2022
Perception, Radiation, Congress, Cancer, GLOBE, European Journal of Nuclear Medicine and Molecular Imaging, Association, Nasdaq, Research, Abstract (summary), European Association of Urology, European Journal, Feasibility, Safety, Glioblastoma, Liposome, Neoplasm, PSTV, Therapy, EANM, Molecular imaging, Springer, Patient, Nuclear medicine, EDT, Company, U.S. Securities and Exchange Commission, Pharmaceutical industry

For more information on the EANM Annual Congress visit, https://eanm22.eanm.org/ .

Key Points: 
  • For more information on the EANM Annual Congress visit, https://eanm22.eanm.org/ .
  • Plus Therapeutics, Inc. isa clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases.
  • Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology.
  • This press release contains statements that may be deemed forward-looking statements within the meaning of U.S. securities laws.

Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas

Retrieved on: 
Giovedì, Settembre 22, 2022
National, Safety, Lone Star, Radiation, DSMB, Food, PSTV, Organization, Company, Therapy, Hand, Neoplasm, Patient, Program, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Texas Legislature, U.S. Securities and Exchange Commission, Perception, Nasdaq, Fast Track, CNS, Data monitoring committee, Research, Conference, GLOBE, LM, NIH, Pharmaceutical industry, Risk management, Cohort

AUSTIN, Texas, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that it has finalized and signed a grant contract with the Cancer Prevention & Research Institute of Texas (CPRIT) for its previously announced $17.6 million Product Development Research funding award. The award will cover the majority of the development costs of the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), for the treatment of patients with leptomeningeal metastases (LM) over a three-year period, beginning in the fourth quarter of 2022.

Key Points: 
  • This award from CPRIT significantly strengthens the companys balance sheet, said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
  • Currently, our two lead CNS cancer programs are externally funded through Phase 2 and multiple clinical milestones.
  • In 2019, Texas voters again voted overwhelmingly to continue CPRIT with an additional $3 billion for a total $6 billion investment in cancer research and prevention.
  • To date, CPRIT has awarded over $3 billion in grants to Texas research institutions and organizations through its academic research, prevention and product development research programs.

Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022

Retrieved on: 
Lunedì, Settembre 12, 2022
Adult, Plus, Safety, Radiation, Type, Survival rate, Brain, FDA, Food, PSTV, Liposome, CGMP, Neoplasm, MRI, Company, European Society for Medical Oncology, Senior, GBM, Therapy, University, Glioblastoma, Survival, Patient, Clinical trial, Cancer, U.S. Securities and Exchange Commission, Oncology, Grey, Perception, DLT, Nasdaq, Neurosurgery, Tram, SPECT, Research, University of Texas System, Rhenium, GLOBE, Congress, CED, Neurology, Glioma, NIH, Food and Drug Administration, ESMO, Pharmaceutical industry, Medical imaging

AUSTIN, Texas, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced Phase 1 data from the ReSPECT-GBM Phase 1/2a dose escalation clinical trial evaluating the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in recurrent glioblastoma (GBM) in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022, being held September 9-13, 2022 in Paris, France.

Key Points: 
  • Radiation is lethal to cancer cells and rhenium-186 is an ideal radioisotope for the treatment of glioblastoma.
  • No dose-limiting toxicities (DLT) have been observed and the procedure is very well tolerated with a strong safety profile.
  • Minimal systemic radiation has been observed and the majority of adverse events have been mild or moderate and considered causally unrelated to the procedure.
  • The Company intends to begin the ReSPECT-GBM Phase 2 trial utilizing cGMP 186RNL drug, which will be available in the second half of 2022.

Plus Therapeutics to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Giovedì, Settembre 8, 2022
Neoplasm, Cancer, Safety, PSTV, Research, Perception, Therapy, Radiation, U.S. Securities and Exchange Commission, GLOBE, Conference, Company, Lotte New York Palace Hotel, Plus, Patient, Pharmaceutical industry

The conference is being held at the Lotte New York Palace Hotel in New York City.

Key Points: 
  • The conference is being held at the Lotte New York Palace Hotel in New York City.
  • Investors interested in arranging an in-person meeting with the Companys management during the conference should contact the H.C. Wainwright conference coordinator.
  • An archived replay of the presentation will be available under the Events tab of the Plus Therapeutics website at www.plustherapeutics.com for 90 days following the event.
  • Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases.